Compare BMA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMA | IMVT |
|---|---|---|
| Founded | 1966 | 2018 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.3B |
| IPO Year | 2006 | N/A |
| Metric | BMA | IMVT |
|---|---|---|
| Price | $91.26 | $26.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $96.33 | $27.75 |
| AVG Volume (30 Days) | 323.4K | ★ 1.9M |
| Earning Date | 11-26-2025 | 02-05-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,943,401,172.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.56 | N/A |
| P/E Ratio | $36.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.30 | $12.72 |
| 52 Week High | $118.42 | $27.69 |
| Indicator | BMA | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 63.69 |
| Support Level | $89.18 | $26.35 |
| Resistance Level | $93.50 | $27.64 |
| Average True Range (ATR) | 4.18 | 1.36 |
| MACD | -0.15 | 0.16 |
| Stochastic Oscillator | 75.49 | 84.89 |
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.